Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials

Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for... Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials a b a B. Greg Brown , Karen Hinckley Stukovsky and Xue-Qiao Zhao Purpose of review Abbreviations Our analysis presents an alternative hypothesis to the HDL high-density lipoprotein LDL low-density lipoprotein prevailing view that low-density lipoprotein-C is the only QCA quantitative coronary arteriography important target of lipid therapy. Recent findings 2006 Lippincott Williams & Wilkins Two recently published studies showed surprising results. 0957-9672 In the Armed Forces Regression Study, low-density lipoprotein-C was lowered only 22% with cholystyramine, niacin and gemfibrozil. Coronary stenosis regressed, Introduction however, and the primary clinical event rate was reduced by In this report, we review the epidemiologic studies that 54%. Conversely, in the FIELD trial, the primary event rate confirm and quantify the impact of elevated low-density reduction was only 11% (P¼ NS). These differences lipoprotein (LDL)-C and low high-density lipoprotein appeared to be explained largely by the difference in high- (HDL)-C as major independent determinants of cardio- density lipoprotein response to these regimens (38 vs. 3%). vascular risk. We then describe a meta-analysis of the This meta-analysis http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Lipidology Wolters Kluwer Health

Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials

Zhao, Xue-Qiao
Current Opinion in Lipidology , Volume 17 (6) – Dec 1, 2006
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/simultaneous-low-density-lipoprotein-c-lowering-and-high-density-afcUGNzaL9

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0957-9672
eISSN
1473-6535
DOI
10.1097/MOL.0b013e32800ff750
pmid
17095907
Publisher site
See Article on Publisher Site

Abstract

Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials a b a B. Greg Brown , Karen Hinckley Stukovsky and Xue-Qiao Zhao Purpose of review Abbreviations Our analysis presents an alternative hypothesis to the HDL high-density lipoprotein LDL low-density lipoprotein prevailing view that low-density lipoprotein-C is the only QCA quantitative coronary arteriography important target of lipid therapy. Recent findings 2006 Lippincott Williams & Wilkins Two recently published studies showed surprising results. 0957-9672 In the Armed Forces Regression Study, low-density lipoprotein-C was lowered only 22% with cholystyramine, niacin and gemfibrozil. Coronary stenosis regressed, Introduction however, and the primary clinical event rate was reduced by In this report, we review the epidemiologic studies that 54%. Conversely, in the FIELD trial, the primary event rate confirm and quantify the impact of elevated low-density reduction was only 11% (P¼ NS). These differences lipoprotein (LDL)-C and low high-density lipoprotein appeared to be explained largely by the difference in high- (HDL)-C as major independent determinants of cardio- density lipoprotein response to these regimens (38 vs. 3%). vascular risk. We then describe a meta-analysis of the This meta-analysis

Journal

Current Opinion in Lipidology – Wolters Kluwer Health

Published: Dec 1, 2006

There are no references for this article.